EGFR and glioblastoma: Given the prominent role HER1 plays in promoting GBM, HER1-directed inhibitors such as Gefitinib and Erlotinib are frequently administered but have proven unable to penetrate the blood–brain-barrier, again highlighting the limitations of current HER-directed therapies [56, 86].